I Hindmarch1. 1. University of Surrey, Guildford, Surrey, UK. ian@psychopharma.co.uk
Abstract
OBJECTIVE: To compare cognitive impairment of medications used in social anxiety disorder (SAD). METHODS: Data from peer-reviewed publications (1975-2007) of controlled, crossover design, pharmacodynamic studies on SAD medications in healthy volunteers were analysed. The number of objective psychometrics for each drug/dose level at all time points after dosing, and of instances of statistically significant impairment of cognitive function, enabled calculation of drug-induced cognitive impairment. The magnitude of impairment between drugs was compared using proportional impairment ratios (PIRs). RESULTS: Olanzapine, oxazepam, lorazepam and mianserin had twice the average cognitive toxicity of other treatments. Selective serotonin reuptake inhibitors (SSRIs) impaired cognition to a lesser extent than other pharmacological groupings. There was extensive intra-class variation: fluvoxamine (PIR = 0.08) possessed little detrimental cognitive activity, whereas sertraline (PIR = 5.33) caused impairment over five times the SSRI group average. Benzodiazepines caused noticeable cognitive impairment. CONCLUSIONS: Substantial differences exist, both between and within therapeutic classes, in the behavioural toxicity of medications used for SAD.
OBJECTIVE: To compare cognitive impairment of medications used in social anxiety disorder (SAD). METHODS: Data from peer-reviewed publications (1975-2007) of controlled, crossover design, pharmacodynamic studies on SAD medications in healthy volunteers were analysed. The number of objective psychometrics for each drug/dose level at all time points after dosing, and of instances of statistically significant impairment of cognitive function, enabled calculation of drug-induced cognitive impairment. The magnitude of impairment between drugs was compared using proportional impairment ratios (PIRs). RESULTS:Olanzapine, oxazepam, lorazepam and mianserin had twice the average cognitive toxicity of other treatments. Selective serotonin reuptake inhibitors (SSRIs) impaired cognition to a lesser extent than other pharmacological groupings. There was extensive intra-class variation: fluvoxamine (PIR = 0.08) possessed little detrimental cognitive activity, whereas sertraline (PIR = 5.33) caused impairment over five times the SSRI group average. Benzodiazepines caused noticeable cognitive impairment. CONCLUSIONS: Substantial differences exist, both between and within therapeutic classes, in the behavioural toxicity of medications used for SAD.
Authors: Kendra K Radtke; Peter Bacchetti; Kathryn Anastos; Daniel Merenstein; Howard Crystal; Roksana Karim; Kathleen M Weber; Andrew Edmonds; Anandi N Sheth; Margaret A Fischl; David Vance; Ruth M Greenblatt; Leah H Rubin Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731
Authors: D W Langdon; M P Amato; J Boringa; B Brochet; F Foley; S Fredrikson; P Hämäläinen; H-P Hartung; L Krupp; I K Penner; A T Reder; R H B Benedict Journal: Mult Scler Date: 2011-12-21 Impact factor: 6.312
Authors: T M Eriksson; P Delagrange; M Spedding; M Popoli; A A Mathé; S O Ögren; P Svenningsson Journal: Mol Psychiatry Date: 2011-01-18 Impact factor: 15.992
Authors: Christina K Psomas; Donald R Hoover; Qiuhu Shi; Todd T Brown; David E Vance; Susan Holman; Michael W Plankey; Phyllis C Tien; Kathleen M Weber; Michelle Floris-Moore; Hector H Bolivar; Elizabeth T Golub; Marcia McDonnell Holstad; Kendra K Radtke; Bani Tamraz; Kristine M Erlandson; Leah H Rubin; Anjali Sharma Journal: J Acquir Immune Defic Syndr Date: 2022-07-01 Impact factor: 3.771